Investigation of pharmacokinetics of Ciprofloxacin and Piperacillin/Tazobactam in Patients receiving continuous renal replacement therapy
- Conditions
- Sepsis and acute renal failure (ARF) are two pathological entities that commonly co-exist in patients admitted to intensive care. Antibiotic dosing in septic patients with ARF can be complicated and may result in either underdosing, causing treatment failure and antibiotic resistance, or overdosing resulting in drug toxicity. The aim of this study is to collect pharmacokinetic data for evaluating underdosing or overdosing of ciprofloxacin and piperacillin/tazobactam in RRT.
- Registration Number
- EUCTR2010-021369-66-DE
- Lead Sponsor
- Department of Pharmacy Universitaetsmedizin Mainz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
•Written consent to the clinical trial by the patient or the legal representative
•Continuous renal replacement therapy
•Antibiotic treatment with piperacillin/tazobactam and/or ciprofloxacin
•Every patient has to be older than 18 years
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
•Unreadiness to the clinical trial
•No antibiotic treatment with piperacillin/tazobactam and/or ciprofloxacin
•No continuous renal replacement therapy
•Not older than 18 years
•Other clinical trial
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method